Candida endocarditis represents a life-threatening infection with high mortality rates despite adequate antifungal treatment. Step-down oral treatment with fluconazole or voriconazole represents a treatment option for clinically stable patients. Drug toxicity, however, is reported during azole therapy and can be challenging, especially among patients with multiple comorbidities. This is the first report that highlights the impact of isavuconazole on the corrected QT interval and liver toxicity in a cirrhotic patient with Candida endocarditis.
Righi E., Muser D., Carnelutti A., Pea F., Sartor A., Bassetti M. (2018). Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. DRUGS & THERAPY PERSPECTIVES, 34(8), 402-403 [10.1007/s40267-018-0520-4].
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report
Pea F.;
2018
Abstract
Candida endocarditis represents a life-threatening infection with high mortality rates despite adequate antifungal treatment. Step-down oral treatment with fluconazole or voriconazole represents a treatment option for clinically stable patients. Drug toxicity, however, is reported during azole therapy and can be challenging, especially among patients with multiple comorbidities. This is the first report that highlights the impact of isavuconazole on the corrected QT interval and liver toxicity in a cirrhotic patient with Candida endocarditis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


